FDA outlines steps for individualized drug development

被引：0
|
作者：
Asher Mullard
机构：
来源：
Nature Reviews Drug Discovery | 2021年 / 20卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：91 / 91
相关论文
共 50 条
  • [21] FDA: Evidentiary Standards for Drug Development and Approval
    Katz R.
    NeuroRX, 2004, 1 (3): : 307 - 316
  • [22] New FDA recommendations to speed drug development
    Shalev M.
    Lab Animal, 2006, 35 (3) : 13 - 13
  • [23] FDA's role in anesthetic drug development
    Landow, L
    Kahn, RC
    Wright, C
    ANESTHESIOLOGY, 1999, 90 (03) : 882 - 889
  • [24] FDA regulatory considerations for oncology drug development
    Moon, Hanlim
    Zang, Dae Young
    Ryu, Min-Hee
    Seo, Yeonsook
    Oh, Bitna
    Hwang, Sunjin
    Farrand, Lee
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2024, 12 (04):
  • [25] Flexibility in the FDA approach to orphan drug development
    Hunter, Nina L.
    Rao, Gayatri R.
    Sherman, Rachel E.
    NATURE REVIEWS DRUG DISCOVERY, 2017, 16 (11) : 737 - 738
  • [26] Pediatric drug development in anesthesiology: an FDA perspective
    Schultheis, LW
    Mathis, LL
    Roca, RA
    Simone, AF
    Hertz, SH
    Rappaport, BA
    ANESTHESIA AND ANALGESIA, 2006, 103 (01): : 49 - 51
  • [27] FDA and Evidence-Based Drug Development
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (02) : 10N - 11N
  • [28] FDA asks for input on antibiotic drug development
    Nature Reviews Drug Discovery, 2013, 12 (7) : 494 - 494
  • [29] FDA Guidance on Drug Development for Early AD
    不详
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (04) : 14N - 14N
  • [30] An industry perspective on the FDA Modernization Act 2.0/3.0: potential next steps for sponsors to reduce animal use in drug development
    Carratt, Sarah A.
    de Zafra, Christina L. Zuch
    Oziolor, Elias
    Rana, Payal
    Vansell, Nichole R.
    Mangipudy, Raja
    Vaidya, Vishal S.
    TOXICOLOGICAL SCIENCES, 2024, 203 (01) : 28 - 34
12345